Stay updated with breaking news from Mark Swallow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions...
/PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS...
/PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS...
(0) - Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases - Funding led by Seroba Life Sciences and supported by Théa Open Innovation, eureKARE and existing shareholders PARIS, July 21, 2021 /PRNewswire/ -- Coave Therapeutics (pronounced 'cove'; formerly Horama), a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces a €21.2 million ($25.1 million) expansion of its Series B funding r...
Enterome to Present at Upcoming Conferences News provided by Share this article PARIS, April 7, 2021 /PRNewswire/ -- ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Bélichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences: European Biotech Investor Days: April 7-8 Jefferies Microbiome-based therapeutics Summit: April 22 Jefferies Virt...